These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 731424)

  • 1. In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol.
    Boyd MR; Burka LT
    J Pharmacol Exp Ther; 1978 Dec; 207(3):687-97. PubMed ID: 731424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies on the metabolic activation of the pulmonary toxin, 4-ipomeanol, by rat lung and liver microsomes.
    Boyd MR; Burka LT; Wilson BJ; Sasame HA
    J Pharmacol Exp Ther; 1978 Dec; 207(3):677-86. PubMed ID: 32381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective role of endogenous pulmonary glutathione and other sulfhydryl compounds against lung damage by alkylating agents. Investigations with 4-ipomeanol in the rat.
    Boyd MR; Stiko A; Statham CN; Jones RB
    Biochem Pharmacol; 1982 Apr; 31(8):1579-83. PubMed ID: 7092947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal toxicity due to reactive metabolites formed in situ in the kidney: investigations with 4-ipomeanol in the mouse.
    Boyd MR; Dutcher JS
    J Pharmacol Exp Ther; 1981 Mar; 216(3):640-6. PubMed ID: 7205642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and metabolism of the pulmonary alkylating agent and cytotoxin, 4-ipomeanol, in control and diethylmaleate-treated rats.
    Statham CN; Boyd MR
    Biochem Pharmacol; 1982 Apr; 31(8):1585-9. PubMed ID: 7092948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species and strain differences in target organ alkylation and toxicity by 4-ipomeanol. Predictive value of covalent binding in studies of target organ toxicities by reactive metabolites.
    Dutcher JS; Boyd MR
    Biochem Pharmacol; 1979 Dec; 28(23):3367-72. PubMed ID: 119540
    [No Abstract]   [Full Text] [Related]  

  • 7. The in vitro formation of glutathione conjugates with the microsomally activated pulmonary bronchiolar aklylating agent and cytotoxin, 4-ipomeanol.
    Buckpitt AR; Boyd MR
    J Pharmacol Exp Ther; 1980 Oct; 215(1):97-103. PubMed ID: 7452496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between the catalytic activities of rabbit pulmonary cytochrome P-450 isozymes and the lung-specific toxicity of the furan derivative, 4-ipomeanol.
    Wolf CR; Statham CN; McMenamin MG; Bend JR; Boyd MR; Philpot RM
    Mol Pharmacol; 1982 Nov; 22(3):738-44. PubMed ID: 7155130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of metabolic activation in the pathogenesis of chemically induced pulmonary disease: mechanism of action of the lung-toxic furan, 4-ipomeanol.
    Boyd MR
    Environ Health Perspect; 1976 Aug; 16():127-38. PubMed ID: 1017416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipomeanol 4-glucuronide, a major urinary metabolite of 4-ipomeanol in the rat.
    Statham CN; Dutcher JS; Kim SH; Boyd MR
    Drug Metab Dispos; 1982; 10(3):264-7. PubMed ID: 6125360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of carbon monoxide on the cytochrome P-450-mediated activation of 4-ipomeanol by the isolated perfused rabbit lung.
    Trela BA; Carlson GP; Turek J; Rebar A; Mathews JM
    J Toxicol Environ Health; 1989; 27(3):341-50. PubMed ID: 2754758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical toxicology studies of 4-ipomeanol: a novel candidate for clinical evaluation in lung cancer.
    Smith AC; Barrett D; Stedham MA; el-Hawari M; Kastello MD; Grieshaber CK; Boyd MR
    Cancer Treat Rep; 1987 Dec; 71(12):1157-64. PubMed ID: 3690525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP4B1 activates 4-ipomeanol in rat lung.
    Verschoyle RD; Philpot RM; Wolf CR; Dinsdale D
    Toxicol Appl Pharmacol; 1993 Dec; 123(2):193-8. PubMed ID: 8248926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of tolerance to the pulmonary toxin, 4-ipomeanol.
    Boyd MR; Burka LT; Wilson BJ; Sastry BV
    Toxicology; 1981; 19(2):85-100. PubMed ID: 6791310
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic activation and cytotoxicity of 4-ipomeanol in human non-small cell lung cancer lines.
    Falzon M; McMahon JB; Schuller HM; Boyd MR
    Cancer Res; 1986 Jul; 46(7):3484-9. PubMed ID: 3011249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic basis for the pulmonary Clara cell as a target for pulmonary carcinogenesis.
    Boyd MR; Reznik-Schüller HM
    Toxicol Pathol; 1984; 12(1):56-61. PubMed ID: 6387866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole body plethysmography as a noninvasive assay of toxic lung injury in mice: studies with the pulmonary alkylating agent and cytotoxin, 4-ipomeanol.
    Travis EL; Brightwell D; Aiken M; Boyd MR
    Toxicol Appl Pharmacol; 1982 Nov; 66(2):193-200. PubMed ID: 7164098
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
    Rowinsky EK; Noe DA; Ettinger DS; Christian MC; Lubejko BG; Fishman EK; Sartorius SE; Boyd MR; Donehower RC
    Cancer Res; 1993 Apr; 53(8):1794-801. PubMed ID: 8467498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covalent binding of metabolites of 4-ipomeanol to rabbit pulmonary and hepatic microsomal proteins and to the enzymes of the pulmonary cytochrome P-450-dependent monooxygenase system.
    Slaughter SR; Statham CN; Philpot RM; Boyd MR
    J Pharmacol Exp Ther; 1983 Jan; 224(1):252-7. PubMed ID: 6848746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity.
    Smith RD; Kehrer JP
    Cancer Res; 1991 Jan; 51(2):542-8. PubMed ID: 1985772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.